The following table represents a list of therapeutics known to be effective against the Omicron variant of COVID-19, and currently authorized or approved by the FDA in the U.S.. Further detailed information is available at the NIH COVID Treatment Guidelines. Additionally, the CDC maintains a list of high risk medical conditions.
800 mg q12hr x 5 days
3.5 kg-40 kg 5mg/kg IV day 1, then 2.5 mg/kg daily
>40 kg 200mg IV day 1, then 100 mg IV daily
175 mg IV, once
300 mg IM
300 mg IM
6 mg daily x 10 days
Bamlanivimab and Etesevimab (administered together) and REGEN-COV (casirivimab and imdevimab) authorization for use in the U.S. was rescinded by the FDA due to a lack of efficacy against the Omicron variant of COVID-19. Additionally, as of 4/5/2022, the use of Sotrovimab is also no longer authorized by the FDA due to evidence of reduced efficacy against the Omicron sub-variant BA.2. Lastly, the dosing for Pxalovid was updated on 4/14/2022 to reflect recommendations for renal dosing.
The U.S. Department of Health & Human Services has two websites available to help find government distributed medications for the treatment of COVID-19:
- COVID-19 Therapeutics Locator– includes a U.S. map of locations receiving Paxlovid, Molnupiravir, and Evusheld
- Therapeutics Distribution– includes a U.S. map of sites receiving monoclonal antibodies but has not been updated since Oct 2021, and does not include Sotrovimab.
Last Updated on April 24, 2022